SmallCaps
ASX:SNTPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

SYNTARA ORD

$0.034
+$0.001 (+1.49%)
Day Range
$0.032 - $0.034
52 Week Range
$0.023 - $0.083
Volume
608.31K
Avg Volume (10D)
671.50K
Market Cap
$55.56M
Price Chart
Market Statistics
Open$0.033
Previous Close$0.034
Day High$0.034
Day Low$0.032
52 Week High$0.083
52 Week Low$0.023
Valuation
Market Cap55.56M
Shares Outstanding1.63B
Price to Book5.23
Trading Activity
Volume608.31K
Value Traded20.07K
Bid$0.033 × 11,944
Ask$0.034 × 1,726,465
Performance
1 Day0.00%
5 Day3.03%
13 Week0.00%
52 Week-30.61%
YTD-2.86%
Technical Indicators
RSI (14)60.66
50-Day SMA$0.032
200-Day SMA$0.034
Latest News
Syntara advances myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation
Biotechnology

Syntara advances myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation

Clinical-stage drug developer Syntara (ASX: SNT) has hit more milestones with its SNT-5505 blood cancer treatment candidate. The company informed shareholders that it has obtained further positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 in combination with ruxolitinib  (RUX) for the treatment of myelofibrosis. Myelofibrosis is a type of blood cancer […]

1 min read
Colin Hay
Colin Hay